Intellia Therapeutics: At the Forefront of Gene Therapy Revolution, Analysts Optimistic Despite Mixed Responses

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been the subject of intense scrutiny by the financial analysts and market investors alike. The company, which is at the forefront of developing gene therapy treatments for genetic disorders using CRISPR/Cas9 technology, has garnered a consensus rating of “Moderate Buy” from twenty analysts as reported in Bloomberg.com.

The analysts are impressed with Intellia’s innovative approach towards gene editing, which they believe has immense potential in terms of addressing a wide range of genetic disorders. Furthermore, several industry experts have acknowledged the advantages offered by Intellia’s proprietary CRISPR/Cas9 technology over conventional gene-editing techniques.

Despite being relatively new to the market, Intellia has managed to amass a significant following among investors due to its potential to revolutionize modern medicine. As such, it doesn’t come as a surprise that sixteen out of twenty equity research analysts have assigned a “Buy” recommendation on NTLA stock.

However, NTLA’s ambitious business strategies may not be everyone’s cup of tea. One researcher has expressed his concern regarding the company’s recent revenue generation and rated it with a “Sell” recommendation. Additionally, three other analysts have also advised investors to stick with existing holdings suggesting only “Hold.”

Despite some mixed responses amongst industry experts and risk-averse investors, those backing Intellia’s proposition remain optimistic based on various fundamental traits― high quality products and services coupled with an innovative stance keeping pace with continuous modernization necessary in today’s dynamic world ― all evidence pointing towards long-term success.

In conclusion, with an average twelve-month price target set at $ 84.18 per share; Intellia Therapeutics Inc.’s steadily growing reputation within scientific community along with its constantly evolving product line creates an intriguing investment opportunity for those willing to take calculated risks associated therein.

Intellia Therapeutics Under Scrutiny from Equities Research Analysts and Institutional Investors


Intellia Therapeutics, a leading biotechnology company that specializes in genome editing and target gene regulation, has recently come under scrutiny from several equities research analysts. This has led to modifications in holdings from institutional investors and hedge funds in the last quarter.

JMP Securities lowered their rating of Intellia Therapeutics from “outperform” to “market perform,” indicating that they believe the stock will be more on par with market averages than exceeding them. In contrast, SVB Leerink remains bullish about the stock’s potential, rating it an “outperform,” but reducing their target price from $86.00 to $84.00.

Oppenheimer also views Intellia Therapeutics favorably, designating it as an “outperform” with a price objective of $93.00 – down from their initial prediction of $115.00.

Other analysts are less optimistic about Intellia Therapeutics’ future prospects. StockNews.com issued a “sell” rating for the company despite starting coverage on its shares in mid-March.

Wells Fargo & Company revised their rating for Intellia Therapeutics as well, decreasing their target price per share from $135.00 to $120.00 while maintaining an “overweight” rating for the company, indicating confidence that the stock will outperform industry averages.

These analysts’ ratings have already influenced some institutional investors and hedge funds to reconsider their holdings related to this stock. Morgan Stanley increased its stake by 64.5% during the fourth quarter and now holds nearly 2.5 million shares valued at almost $88 million.

Norges Bank also entered into a new position with Intellia Therapeutics in Q4 2020 worth approximately $30 million while State Street Corp increased its holdings by over 746K shares during that same period to reach over 3 million total shares valued at over $162 million.

ARK Investment Management LLC was another hedge fund that lifted its holdings during the last quarter by an additional 416,000 shares. Nomura Holdings, Inc. made the most dramatic increase in holdings of all by acquiring nearly 400K shares – a lift of over 235%.

Combined, institutional investors and hedge funds now own over 85% of Intellia Therapeutics’ stock. As the biotech industry continues to grow and evolve, analysts and investors alike will undoubtedly remain focused on companies that can deliver innovative solutions to some of our world’s most intractable health issues.

Read more here: Source link